• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Generation of chimeric antigen receptors with different reactivity for a tumor antigen

Research Project

Project/Area Number 16H07025
Research Category

Grant-in-Aid for Research Activity Start-up

Allocation TypeSingle-year Grants
Research Field Hematology
Research InstitutionEhime University

Principal Investigator

Ochi Toshiki  愛媛大学, 医学系研究科, 講師 (10571086)

Project Period (FY) 2016-08-26 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywordsキメラ抗原受容体 / 一本鎖抗体 / NY-ESO-1 / scFvライブラリー / トランスレーショナルリサーチ / がん免疫療法 / 免疫グロブリン遺伝子ライブラリー
Outline of Final Research Achievements

Modified antibodies which activate immune cells with cancer specificity has been developed, thereby cancer immunotherapy has shown great success. In this study, we focused on optimizing single chain fragment variables (scFvs) for further development of antibody-based immunotherapy. Using chimeric antigen receptor T cells (CAR-T cells) and an HLA-A2/NY-ESO-1 complex expressed by tumor cells as models, we have established a new scFv generation system which can fine-tune the reactivity of CAR-T cells. Newly generated scFv-expressing CAR-T cells showed target-specific reactivity with different degrees. Among them, we have successfully identified scFv-optimized CAR-T cells which show sufficient antitumor reactivity with minimal unwanted cross-reactivity. This system allows us to optimize each scFv for each antibody-based modality, resulting in the advancement of successful cancer immunotherapy utilizing modified antibodies.

Academic Significance and Societal Importance of the Research Achievements

我々が確立した新規技術を用いれば、scFv内の可変領域配列を自由に変化させることで、scFvの標的認識様式を繊細に調律することが可能となる。そして、CAR-T細胞の抗がん活性を指標としながら新規scFvを作製・同定することが可能となる。本技術を応用すれば、様々な抗体製剤の治療効果に主眼においたこれまでにはない迅速かつ網羅的な抗体医薬品作製が可能となるため、がんを含めた難治性疾患に対する免疫療法製剤開発の領域におけるインパクトは大きく、社会的意義も高いと考えられる。

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Annual Research Report
  • Research Products

    (13 results)

All 2018 2017

All Journal Article (2 results) Presentation (11 results) (of which Int'l Joint Research: 4 results,  Invited: 3 results)

  • [Journal Article] 遺伝子改変抗体を応用したがんに対する T細胞免疫療法2018

    • Author(s)
      越智俊元
    • Journal Title

      愛媛医学

      Volume: 37

    • Related Report
      2017 Annual Research Report
  • [Journal Article] 白血病幹細胞の免疫細胞治療2018

    • Author(s)
      越智俊元
    • Journal Title

      血液フロンティア

      Volume: 6

    • Related Report
      2017 Annual Research Report
  • [Presentation] Anti-myeloma T-cell therapy by exploiting modified antibodies specific for A2/NY-ESO-12018

    • Author(s)
      Ochi, T.
    • Organizer
      4th Annual Immunotherapy in Myeloma Scientific Workshop
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] Strategically Comprehensive Immunotherapy Utilizing Modified Antibody Targeting NY-ESO-1 for Myeloma2017

    • Author(s)
      Maruta, M., Ochi, T., Fujiwara, H., Yasukawa, M.
    • Organizer
      The 8th JSH International Symposium
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Development of immunotherapy for myeloma utilizing T cells redirected with modified antibodies specific for NY-ESO-12017

    • Author(s)
      Ochi, T., Maruta, M., Tanimoto, K., Azuma, T., Fujiwara, H., Yasukawa M.
    • Organizer
      The 36th Sapporo International Cancer Symposium
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Development of T-cell therapy by exploiting modified antibodies specific for A2/NY-ESO-1 for refractory myeloma2017

    • Author(s)
      Maruta, M., Ochi, T., Tanimoto, K., Azuma, T., Fujiwara, H., Yasukawa, M.
    • Organizer
      The 59th American Society of Hematology Annual Meeting and Exposition
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Anti-myeloma immunotherapy utilizing T cells redirected by modified antibodies targeting NY-ESO-12017

    • Author(s)
      Ochi, T., Maruta, M., Fujiwara, H., Yasukawa M.
    • Organizer
      第42回日本骨髄腫学会学術集会
    • Related Report
      2017 Annual Research Report
  • [Presentation] 造血器腫瘍に対する抗原特異的T細胞を用いた免疫遺伝子治療2017

    • Author(s)
      越智俊元
    • Organizer
      第45回日本臨床免疫学会総会
    • Related Report
      2017 Annual Research Report
    • Invited
  • [Presentation] NY-ESO-1を認識する改変抗体を応用した骨髄腫に対する新たな包括的免疫療法の開発2017

    • Author(s)
      越智俊元, 丸田雅樹, 藤原弘, 安川正貴
    • Organizer
      第54回日本臨床分子医学会学術集会
    • Related Report
      2017 Annual Research Report
  • [Presentation] A2/NY-ESO-1特異的改変抗体を応用した多発性骨髄腫に対する新規免疫療法の開発2017

    • Author(s)
      丸田雅樹, 越智俊元, 谷本一史, 東太地, 藤原弘, 安川正貴
    • Organizer
      第21回日本がん免疫学会総会
    • Related Report
      2017 Annual Research Report
  • [Presentation] A2/NY-ESO-1特異的改変抗体を応用した骨髄腫に対する新たな免疫療法の開発2017

    • Author(s)
      越智俊元, 丸田雅樹, 谷本一史, 東太地, 藤原弘, 安川正貴
    • Organizer
      第9回血液疾患免疫療法学会
    • Related Report
      2017 Annual Research Report
  • [Presentation] 改変抗体を応用した多発性骨髄腫に対する新たな免疫療法の開発2017

    • Author(s)
      丸田雅樹, 越智俊元, 藤原弘, 安川正貴
    • Organizer
      第79回日本血液学会学術集会
    • Related Report
      2017 Annual Research Report
  • [Presentation] T細胞を応用した造血器腫瘍に対する免疫療法2017

    • Author(s)
      越智俊元
    • Organizer
      平成29年度高知大学大学院医学専攻DCセミナー
    • Related Report
      2017 Annual Research Report
    • Invited

URL: 

Published: 2016-09-02   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi